• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BioFactors >Less increase of copeptin and MR-proADM due to intervention with selenium and coenzyme Q10 combined: Results from a 4-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens
【24h】

Less increase of copeptin and MR-proADM due to intervention with selenium and coenzyme Q10 combined: Results from a 4-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens

机译：硒和辅酶Q10联合干预后，肽素和MR-proADM的增加较少：瑞典老年人中一项为期4年的前瞻性随机双盲安慰剂对照试验的结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Intervention with selenium and coenzyme Q10 have recently been found to reduce mortality and increase cardiac function. The mechanisms behind these effects are unclear. As selenium and coenzyme Q10 is involved in the anti-oxidative defence, the present study aimed to evaluate effects of selenium and coenzyme Q10 on copeptin and adrenomedullin as oxidative stress biomarkers. Therefore 437 elderly individuals were included and given intervention for 4 years. Clinical examination and blood samples were undertaken at start and after 18 and 48 months. Evaluations of copeptin and MR-proADM changes were performed using repeated measures of variance. Cardiovascular mortality was evaluated using a 10-year-period of follow-up, and presented in Kaplan-Meier plots. A significant increase in copeptin level could be seen in the placebo group during the intervention period (from 9.4 pmol/L to 15.3 pmol/L), compared to the active treatment group. The difference between the groups was confirmed in the repeated measurement of variance analyses (P=0.031) with less copeptin increase in the active treatment group. Furthermore, active treatment appeared to protect against cardiovascular death both in those with high and with low copeptin levels at inclusion. Less increase of MR-proADM could also be seen during the intervention in the active treatment group compared to controls (P=0.026). Both in those having an MR-proADM level above or below median level, significantly less cardiovascular mortality could be seen in the active treatment group (P=0.0001, and P=0.04 respectively). In conclusion supplementation with selenium and coenzyme Q10 during four years resulted in less concentration of both copeptin and MR-proADM. A cardioprotective effect of the supplementation was registered, irrespective of the initial levels of these biomarkers, and this protection was recognized also after 10 years of observation. (c) 2015 BioFactors, 41(6):443-452, 2015
机译：最近发现，硒和辅酶Q10的干预可降低死亡率并增强心脏功能。这些影响的机制尚不清楚。由于硒和辅酶Q10参与抗氧化防御，本研究旨在评估硒和辅酶Q10对作为氧化应激生物标记物的肽素和肾上腺髓质素的影响。因此，纳入了437名老年人，并对其进行了4年的干预。在开始时以及18和48个月后进行临床检查和血液样本。使用重复的方差测量来评估肽素和MR-proADM的变化。使用10年的随访时间评估心血管疾病的死亡率，并以Kaplan-Meier图表显示。与积极治疗组相比，在干预期间，安慰剂组的肽素水平显着增加（从9.4 pmol / L增至15.3 pmol / L）。在重复测量的方差分析中证实了组之间的差异（P = 0.031），而活性治疗组的肽素增加较少。此外，积极治疗似乎可以预防包含高和低肽素水平的人的心血管死亡。与对照组相比，在积极治疗组进行干预期间，MR-proADM的增加也较少（P = 0.026）。在MR-proADM水平高于或低于中值水平的患者中，在积极治疗组中均可以观察到明显更低的心血管死亡率（分别为P = 0.0001和P = 0.04）。总之，在四年中补充硒和辅酶Q10会导致肽素和MR-proADM的浓度降低。不论这些生物标志物的初始水平如何，都记录了该补充剂的心脏保护作用，并且在观察了10年后，这种保护作用也得到了认可。 （c）2015生物因子，2015，41（6）：443-452

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号